NYSE:NVO - Novo Nordisk Stock Price, Price Target & More

Novo Nordisk trades on the New York Stock Exchange (NYSE) under the ticker symbol "NVO."

Novo Nordisk announced a special dividend on Monday, February 5th. Stockholders of record on Monday, March 26th will be given a dividend of $0.8117 per share on Tuesday, April 3rd. This represents a dividend yield of 0.96%. The ex-dividend date of this dividend is Friday, March 23rd. View Novo Nordisk's Dividend History.

Novo Nordisk announced that its Board of Directors has initiated a stock repurchase program on Friday, February 2nd 2018, which permits the company to buyback shares, according to EventVestor. This buyback authorization permits the company to reacquire shares of its stock through open market purchases. Stock buyback programs are usually a sign that the company's board believes its stock is undervalued.

Novo Nordisk (NYSE:NVO) announced its quarterly earnings results on Thursday, February, 1st. The company reported $0.53 earnings per share (EPS) for the quarter, missing the Zacks' consensus estimate of $0.57 by $0.04. The firm earned $4.43 billion during the quarter, compared to analyst estimates of $4.27 billion. Novo Nordisk had a return on equity of 82.72% and a net margin of 34.09%. View Novo Nordisk's Earnings History.

Novo Nordisk is scheduled to release their next quarterly earnings announcement on Wednesday, May, 2nd 2018. View Earnings Estimates for Novo Nordisk.

Novo Nordisk saw a decline in short interest in March. As of March 29th, there was short interest totalling 1,255,045 shares, a decline of 42.5% from the March 15th total of 2,182,514 shares. Based on an average trading volume of 1,221,682 shares, the short-interest ratio is currently 1.0 days. Currently, 0.1% of the company's stock are sold short.

Some companies that are related to Novo Nordisk include Pfizer (PFE), Novartis (NVS), Merck & Co. (MRK), AbbVie (ABBV), Abbott Laboratories (ABT), Bayer (BAYRY), Sanofi (SNY), GlaxoSmithKline (GSK), AstraZeneca (AZN), Eli Lilly and (LLY), Bristol-Myers Squibb (BMY), Celgene (CELG), Allergan (AGN), Shire (SHPG), Zoetis (ZTS), Vertex Pharmaceuticals (VRTX), Takeda Pharmaceutical (TKPYY) and Regeneron (REGN).

Media stories about NVO stock have been trending somewhat negative on Monday, according to Accern Sentiment. Accern rates the sentiment of press coverage by monitoring more than twenty million news and blog sources. Accern ranks coverage of public companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Novo Nordisk earned a news sentiment score of -0.02 on Accern's scale. They also gave media coverage about the company an impact score of 46.14 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the company's share price in the next several days.

Shares of NVO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

One share of NVO stock can currently be purchased for approximately $46.97.

Novo Nordisk has a market capitalization of $115.41 billion and generates $16.96 billion in revenue each year. The company earns $5.79 billion in net income (profit) each year or $2.34 on an earnings per share basis. Novo Nordisk employs 42,076 workers across the globe.

Novo Nordisk's mailing address is Novo Alle, Bagsvaerd G7, 2880. The company can be reached via phone at 45-4444-8888 or via email at [email protected]